POSTMENOPAUSAL BMD

比较绝经后妇女每周服用35 mg阿仑磷酸钠1次和每天服用5 mg阿仑磷酸钠对腰椎骨密度的影响。目的：评估绝经后妇女每周服用35 mg阿仑磷酸钠1年与每日服用5 mg阿伦磷酸钠的安全性和耐受性。目的：比较绝经后妇女每周服用阿仑磷酸钠35 mg与每日服用5 mg治疗1年后髋部和全身骨密度的变化。目的：通过生化标记物(NTX和BSAP)对绝经后妇女骨转换率的评估，评估每周服用35 mg阿伦磷酸钠1年和2年与每天服用5 mg阿伦磷酸钠治疗1年和2年的效果。目的：评估绝经后妇女每周服用一次35毫克阿伦磷酸钠与每天服用5毫克阿伦磷酸钠治疗2年对(A)腰椎、髋部和全身骨密度的影响，以及(B)安全性和耐受性。

To compare the effects on lumbar spine BMD of 1 year of treatment with alendronate 35 mg once weekly compared to treatment with 5 mg daily in postmenopausal women. To assess the safety and tolerablility of 1 year of treatment with alendronate 35 mg once weekly compared to treatment with 5 mg daily in postmenopausal women. To compare the effects of BMD of the hip and total body of 1 year treatment with alendronate 35 mg once weekly with those of 5 mg daily in postmenopausal women. To assess the effect of 1 and 2 years of treatment with alendronate 35 mg once weekly compared to treatment with alendronate 5 mg daily on the rate of bone turnover as assessed by biochemical markers (NTx and BSAP) in postmenopausal women. To assess the effect of 2 years of treatment with alendronate 35 mg once weekly compared to treatment with alendronate 5 mg daily in postmenopausal women on (a) BMD at the lumbar spine, hip, and total body, and (b) safety and tolerability.